Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Consumer Sales Buoyed By Listerine In Third Quarter

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's Listerine mouthwash brand achieved double-digit growth in its most recent quarter, fueled by international sales and the recent U.S. launch of Whitening Quick Dissolving Strips, the firm said Oct. 16

You may also be interested in...



Johnson & Johnson Starts Downsizing Plan, PCH Integration Stays On Track

Johnson & Johnson executives are touting the strength of the firm's consumer products businesses as they implement a plan to generate up to $1.6 billion in savings through consolidations and layoffs in J&J's pharmaceutical and medical device operations

J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business

SafetyCall On What Cosmetics Companies Need In Their AE Reporting Systems

Companies preparing for adverse event reporting and recordkeeping deadlines on 29 December under new cosmetics regulations should ensure they have systems in place for netting complaints across media, triaging reports, and making speedy weight-of-evidence determinations, said SafetyCall International’s Rick Kingston at IBA’s recent FDA regulatory workshop.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel